Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
med-mastodon.com is one of the many independent Mastodon servers you can use to participate in the fediverse.
Medical community on Mastodon

Administered by:

Server stats:

345
active users

med-mastodon.com: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.8

#DrugDevelopment

0 posts0 participants0 posts today
Public
ResearchBuzz: Firehose

ZDNet: This AI-designed drug for IBD was just given to human subjects for the first time. “While drugs are being developed using AI in a variety of ways, no drugs developed completely by AI, from start to finish, have so far made it over the finish line of regulatory approval. For that reason, every attempt by an AI drug to get approval is a landmark of sorts. Tuesday, drug development […]

https://rbfirehose.com/2025/05/16/zdnet-this-ai-designed-drug-for-ibd-was-just-given-to-human-subjects-for-the-first-time/

#absci#ai#aiassisted
Public
Healthcare Tech Robot

DATE: October 18, 2024 at 07:00AM
SOURCE: BioWorld MedTech

Direct article link at end of text block below.

BioWorld Insider podcast: A quantum leap into the future of drug development

t.co/SsK0EsnSB2

#medtech @BioWorld #podcast #drugdevelopment

Here are any URLs found in the article text:

t.co/SsK0EsnSB2

#medtech

Articles can be found by scrolling down the page at bioworld.com/topics/85-bioworl .

-------------------------------------------------

Private, vetted email list for mental health professionals: clinicians-exchange.org
.
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
.
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: nationalpsychologist.com
.
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE:
subscribe-article-digests.clin
.
READ ONLINE: read-the-rss-mega-archive.clin
.
It's primitive... but it works... mostly...
.
-------------------------------------------------

t.coBioWorld Insider podcast: A quantum leap into the future of drug developmentBy Lee Landenberger
#healthcare#healthtech#healthcaretech
Public
Healthcare Tech Robot

DATE: October 17, 2024 at 05:00PM
SOURCE: BioWorld MedTech

Direct article link at end of text block below.

BioWorld Insider podcast: A quantum leap into the future of drug development

t.co/SsK0EsnSB2

#medtech @BioWorld #podcast #drugdevelopment

Here are any URLs found in the article text:

t.co/SsK0EsnSB2

#medtech

Articles can be found by scrolling down the page at bioworld.com/topics/85-bioworl .

-------------------------------------------------

Private, vetted email list for mental health professionals: clinicians-exchange.org
.
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
.
Since 1991 The National Psychologist has focused on keeping practicing psychologists current with news, information and items of interest. Check them out for more free articles, resources, and subscription information: nationalpsychologist.com
.
EMAIL DAILY DIGEST OF RSS FEEDS -- SUBSCRIBE:
subscribe-article-digests.clin
.
READ ONLINE: read-the-rss-mega-archive.clin
.
It's primitive... but it works... mostly...
.
-------------------------------------------------

t.coBioWorld Insider podcast: A quantum leap into the future of drug developmentBy Lee Landenberger
#healthcare#healthtech#healthcaretech
Public
katch wreck

"Sequential cleavage of the first and last tether, with washing in between, ensured that the final library comprises only the fully complete compounds. The outstanding purity attained by this approach enables a direct correlation of #chemical display and encoding, allows for an increased chemical reaction scope, and facilitates the use of more diversity elements while achieving greatly improved signal-to-noise ratios in selections."

science.org/doi/10.1126/scienc

#drugDevelopment#biochemistry
Public
Thomas Sandmann

This 2015 article provided me with food for thought this week "Why is it hard to terminate failing projects in pharmaceutical R&D?" nature.com/articles/nrd4725 (pay walled, unfortunately). It does a great job summarizing why it is so hard for teams and individuals to stop projects - despite clear opportunity costs and the high failure rate in drug development. The authors suggest 7 concrete steps toward a quick-kill strategy: #Biotech #DrugDevelopment #Science

Plan for implementing quick-kill strategies « Abandon denialism. Progression-seeking behaviour incurs massive opportunity costs. Focusing on cycle- time reduction in the past meant the industry became really slick at delivering projects that were terminated in later-stage development. « Banish ‘success’ and ‘failure’ from the organizational lexicon. Good decisions — either to progress a market- able product or to terminate an unmarketable product — are all successes. Learn from both kinds. « Rebuild reward systems to reward good decisions rather than good outcomes. « Place project progression targets in a quality frame- work, or abandon them altogether. Targets encourage progression-seeking behaviour and invite gaming of the system, and they do not work in isolation. « Quantify and communicate opportunity costs in the organization. Reframe progression-seeking behaviour in terms of opportunity costs and consider termination decisions as prospective gains rather than losses. « Overhaul feedback systems, in order to allow staff to learn the outcome of early development decisions and avoid repeating the same mistakes. « Develop a communication plan for staff and share- holders that presents the new model and the probable timescales. Communication with the financial markets is particularly important. Is this plan achievable? In our view, it has to be, as continuing to carry the cost of late-stage attrition is too great a burden to the industry and to society.
ExploreLive feeds
About